Tonix Income Tax Expense from 2010 to 2024

TNXP Stock  USD 0.19  0.00  0.00%   
Tonix Pharmaceuticals Income Tax Expense yearly trend continues to be relatively stable with very little volatility. Income Tax Expense is likely to grow to -0.95 this year. During the period from 2010 to 2024, Tonix Pharmaceuticals Income Tax Expense destribution of quarterly values had range of 5 M from its regression line and mean deviation of  1,059,724. View All Fundamentals
 
Income Tax Expense  
First Reported
2008-03-31
Previous Quarter
-1.2 M
Current Value
-1.2 M
Quarterly Volatility
13.1 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tonix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tonix Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 9.6 M, Selling General Administrative of 36.5 M or Gross Profit of 3.2 M, as well as many indicators such as Price To Sales Ratio of 0.7, Dividend Yield of 0.44 or PTB Ratio of 0.0683. Tonix financial statements analysis is a perfect complement when working with Tonix Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Tonix Pharmaceuticals Correlation against competitors.

Latest Tonix Pharmaceuticals' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Tonix Pharmaceuticals Holding over the last few years. It is Tonix Pharmaceuticals' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tonix Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Very volatile
   Income Tax Expense   
       Timeline  

Tonix Income Tax Expense Regression Statistics

Arithmetic Mean610,505
Geometric Mean36,099
Coefficient Of Variation245.83
Mean Deviation1,059,724
Median(17,000)
Standard Deviation1,500,809
Sample Variance2.3T
Range5M
R-Value(0.05)
Mean Square Error2.4T
R-Squared0
Significance0.86
Slope(16,513)
Total Sum of Squares31.5T

Tonix Income Tax Expense History

2024 -0.95
2023 -1.0
20224.8 M
2020-75 K
2019-236 K
2018233 K
2017-70 K

About Tonix Pharmaceuticals Financial Statements

Tonix Pharmaceuticals shareholders use historical fundamental indicators, such as Income Tax Expense, to determine how well the company is positioned to perform in the future. Although Tonix Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Tonix Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tonix Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Income Tax Expense(1.00)(0.95)

Pair Trading with Tonix Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tonix Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tonix Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Tonix Stock

  0.55DNLI Denali TherapeuticsPairCorr
  0.41DOMH Dominari HoldingsPairCorr
The ability to find closely correlated positions to Tonix Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tonix Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tonix Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tonix Pharmaceuticals Holding to buy it.
The correlation of Tonix Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tonix Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tonix Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tonix Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Tonix Stock Analysis

When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.